Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker GENB
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Frances Arnold Director | GENB Generate Biomedicines, Inc. | Sale | 11,409 | $16.19 | $184.7K Sale | Form 4 ↗ |
| Sep 1, 2026 | Frances Arnold Director | GENB Generate Biomedicines, Inc. | Sale | 1,000 | $16.00 | $16.0K Sale | Form 4 ↗ |
| Mar 4, 2026 | Michael Nally Chief Executive Officer, Director | GENB Generate Biomedicines, Inc. | Buy | 20,000 | $12.00 | $240.0K Buy | Form 4 ↗ |
| Mar 2, 2026 | Beth Grous Chief People Officer | GENB Generate Biomedicines, Inc. | Buy | 300 | $16.00 | $4,800 Buy | Form 4 ↗ |
| Mar 2, 2026 | Jason Silvers President & CFO | GENB Generate Biomedicines, Inc. | Buy | 1,000 | $16.00 | $16.0K Buy | Form 4 ↗ |
| Mar 2, 2026 | Jason Silvers President & CFO | GENB Generate Biomedicines, Inc. | Buy | 500 | $16.00 | $8,000 Buy | Form 4 ↗ |
| Mar 2, 2026 | Jason Silvers President & CFO | GENB Generate Biomedicines, Inc. | Buy | 500 | $16.00 | $8,000 Buy | Form 4 ↗ |
| Mar 2, 2026 | Nutritional Health LTP Fund General Partner LLC 10% owner | GENB Generate Biomedicines, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Mar 2, 2026 | Nutritional Health LTP Fund General Partner LLC 10% owner | GENB Generate Biomedicines, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Mar 2, 2026 | Nutritional Health LTP Fund General Partner LLC 10% owner | GENB Generate Biomedicines, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Mar 2, 2026 | Jane L. Mendillo Director | GENB Generate Biomedicines, Inc. | Buy | 1,500 | $16.00 | $24.0K Buy | Form 4 ↗ |
| Mar 2, 2026 | Flagship Pioneering Fund VI, L.P. 10% owner | GENB Generate Biomedicines, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Mar 2, 2026 | Flagship Pioneering Fund VI, L.P. 10% owner | GENB Generate Biomedicines, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
| Mar 2, 2026 | Flagship Pioneering Fund VI, L.P. 10% owner | GENB Generate Biomedicines, Inc. | Buy | 1.56M | $16.00 | $25.0M Buy | Form 4 ↗ |
14 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances